Vaginal Estrogen: The Treatment With a Different Risk Profile Entirely

Genitourinary syndrome of menopause affects roughly 27% to 84% of postmenopausal women, and unlike hot flushes it does not fade with time — it progresses. The position statement of The North American Menopause Society describes it as likely both underdiagnosed and undertreated, while also noting that in most cases symptoms can be managed effectively.[1]

The reason it deserves its own article rather than a paragraph inside a general hormone therapy guide is that local vaginal estrogen is a different intervention from systemic estrogen, with a different risk profile and different rules.

What GSM actually covers

The name changed from "vulvovaginal atrophy" because the older term described only part of it. GSM covers the genital, sexual and urinary consequences of falling estrogen — vaginal dryness, burning and irritation, pain with intercourse, and urinary symptoms including urgency and recurrent urinary tract infections.

Two features make it distinct from vasomotor symptoms:

1. It is progressive. Hot flushes typically diminish over years. Genitourinary tissue changes do not; untreated, they continue.
2. It goes unreported. The NAMS panel's judgement that it is underdiagnosed and undertreated reflects both that women often do not raise it and that clinicians often do not ask.

The consequences are not trivial. The position statement states plainly that GSM can significantly impair health, sexual function and quality of life.[1]

What works

NAMS sets out a tiered set of options, chosen by symptom severity, safety for the individual, and patient preference:[1]

For mild symptoms — over-the-counter vaginal lubricants and moisturisers provide sufficient relief for most women. These are non-hormonal and need no prescription.

For moderate to severe symptoms — four categories are described as effective:

• low-dose vaginal estrogens
• vaginal dehydroepiandrosterone (DHEA)
• systemic estrogen therapy
• ospemifene, an estrogen agonist/antagonist

The rule that surprises people

When low-dose vaginal estrogen or DHEA or ospemifene is administered, a progestogen is not indicated; however, endometrial safety has not been studied in clinical trials beyond 1 year.[1]

This is the practical difference between local and systemic therapy. Systemic estrogen in a woman with a uterus requires endometrial protection — a requirement the FDA explicitly preserved when it removed the other boxed warnings in November 2025. Low-dose vaginal estrogen, acting locally at doses not intended to produce systemic concentrations, is not held to that requirement.

Note the second clause as carefully as the first. "Not indicated" is the guidance; "not been studied beyond 1 year" is the evidence behind it. Those are different statements, and the position statement is being honest by putting them in the same sentence. Long-term endometrial safety data for vaginal estrogen, vaginal DHEA and ospemifene is described as lacking.

What is not established

The position statement is unusually direct about its own gaps, and they are worth carrying:

1. Long-term endometrial safety for vaginal estrogen, vaginal DHEA and ospemifene — not studied beyond a year.
2. Energy-based therapies, including laser. There are insufficient placebo-controlled trials to draw conclusions on efficacy or safety, or to make treatment recommendations.[1] Vaginal laser is marketed for GSM; the evidence base does not currently support recommending it.
3. Women with a history of breast cancer. There are insufficient data to confirm the safety of vaginal estrogen, DHEA or ospemifene in this group, and the statement advises that management should account for the woman's needs and her oncologist's recommendations.[1]

That third point matters because GSM is common after breast cancer treatment — aromatase inhibitors make it worse — so the women with the strongest need often sit in the group with the weakest evidence.

How this fits with systemic therapy

They are not alternatives so much as different scopes.

• GSM only → local therapy is usually the first choice, at the lowest effective dose.
• Vasomotor symptoms and GSM → systemic therapy treats both, and what it treats and what it does not sets out that list.
• Systemic therapy, GSM persisting → local therapy can be added; systemic doses are not always sufficient for genitourinary tissue.

Route matters for systemic therapy in a way it does not for local therapy — the clot-risk difference between oral and transdermal estrogen turns on first-pass liver metabolism that low-dose vaginal preparations largely bypass.

Bottom line

GSM affects a large minority to a large majority of postmenopausal women, progresses rather than resolves, and is under-treated. Lubricants and moisturisers suffice for mild symptoms; low-dose vaginal estrogen, vaginal DHEA, systemic estrogen and ospemifene are all effective for moderate to severe symptoms. Local therapy does not carry the progestogen requirement that systemic estrogen does — a guidance position supported by trials that have not run beyond a year. Laser is not currently supported by evidence, and safety after breast cancer is an open question best handled with an oncologist.

References

1 source

1. The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. doi:10.1097/GME.0000000000001609 · PMID 32852449